Inhibition of the intrinsic but not the extrinsic apoptosis pathway accelerates and drives myc-driven tumorigenesis towards acute myeloid leukemia

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Högstrand, Kari ^a   Hejll, Eduar ^b   Sander, Birgitta ^a   Rozell, Björn ^a   Larsson, Lars Gunnar ^b   Grandien, Alf ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR; FLICE INHIBITORY PROTEIN; MYC PROTEIN; PROTEIN BCL 2; PROTEIN BCL X; BACTERIAL PROTEIN; CFLAR PROTEIN, HUMAN; CFLAR PROTEIN, MOUSE; GREEN FLUORESCENT PROTEIN; MYC PROTEIN, HUMAN; PHOTOPROTEIN; YELLOW FLUORESCENT PROTEIN, BACTERIA;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BCL X GENE; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; FLIP GENE; GENE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; T CELL LYMPHOMA; T LYMPHOCYTE SUBPOPULATION; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; CELL TRANSFORMATION; CYTOLOGY; DBA MOUSE; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELL; KINETICS; METABOLISM; TUMOR CELL LINE;

MUS;

ANIMALS; APOPTOSIS; BACTERIAL PROTEINS; BCL-X PROTEIN; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GREEN FLUORESCENT PROTEINS; HEMATOPOIETIC STEM CELLS; HUMANS; KINETICS; LEUKEMIA, MYELOID, ACUTE; LUMINESCENT PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; MODELS, BIOLOGICAL; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84857663283     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031366     Document Type: Article

References (51)

1. Gilliland DG, Tallman MS, (2002) Focus on acute leukemias. Cancer Cell 1: 417-420.
2. Frankfurt O, Licht JD, Tallman MS, (2007) Molecular characterization of acute myeloid leukemia and its impact on treatment. Curr Opin Oncol 19: 635-649.
3. Muller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, et al. (2004) Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol 24: 2890-2904.
4. Schreiner S, Birke M, Garcia-Cuellar MP, Zilles O, Greil J, et al. (2001) MLL-ENL causes a reversible and myc-dependent block of myelomonocytic cell differentiation. Cancer Res 61: 6480-6486.
5. Meyer N, Penn LZ, (2008) Reflecting on 25 years with MYC. Nat Rev Cancer 8: 976-990.
6. Larsson LG, Henriksson MA, (2010) The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy. Exp Cell Res 316: 1429-1437.
7. Jones L, Wei G, Sevcikova S, Phan V, Jain S, et al. (2010) Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. J Exp Med 207: 2581-2594.
8. Larramendy ML, Niini T, Elonen E, Nagy B, Ollila J, et al. (2002) Overexpression of translocation-associated fusion genes of FGFRI, MYC, NPMI, and DEK, but absence of the translocations in acute myeloid leukemia. A microarray analysis. Haematologica 87: 569-577.
9. Preisler HD, Guan WD, Khan S, Kinniburgh A, (1987) Differing patterns of proto-oncogene expression in immature and mature myeloid cells. Leuk Res 11: 923-934.
10. Kawagoe H, Kandilci A, Kranenburg TA, Grosveld GC, (2007) Overexpression of N-Myc rapidly causes acute myeloid leukemia in mice. Cancer Res 67: 10677-10685.
11. Luo H, Li Q, O'Neal J, Kreisel F, Le Beau MM, et al. (2005) c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood 106: 2452-2461.
12. Nilsson JA, Cleveland JL, (2003) Myc pathways provoking cell suicide and cancer. Oncogene 22: 9007-9021.
13. Meyer N, Kim SS, Penn LZ, (2006) The Oscar-worthy role of Myc in apoptosis. Semin Cancer Biol 16: 275-287.
14. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, et al. (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12: 2424-2433.
15. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL, (1999) Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13: 2658-2669.
16. Eischen CM, Woo D, Roussel MF, Cleveland JL, (2001) Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. Mol Cell Biol 21: 5063-5070.
17. Strasser A, Harris AW, Bath ML, Cory S, (1990) Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348: 331-333.
18. Swanson PJ, Kuslak SL, Fang W, Tze L, Gaffney P, et al. (2004) Fatal acute lymphoblastic leukemia in mice transgenic for B cell-restricted bcl-xL and c-myc. J Immunol 172: 6684-6691.
19. Beverly LJ, Varmus HE, (2009) MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family. Oncogene 28: 1274-1279.
20. Egle A, Harris AW, Bouillet P, Cory S, (2004) Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci U S A 101: 6164-6169.
21. Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, et al. (2005) Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436: 807-811.
22. Hueber AO, Zornig M, Lyon D, Suda T, Nagata S, et al. (1997) Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science 278: 1305-1309.
23. Hoffman B, Liebermann DA, (2008) Apoptotic signaling by c-MYC. Oncogene 27: 6462-6472.
24. Wang Y, Engels IH, Knee DA, Nasoff M, Deveraux QL, et al. (2004) Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 5: 501-512.
25. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, et al. (2000) Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6: 529-535.
26. Zornig M, Grzeschiczek A, Kowalski MB, Hartmann KU, Moroy T, (1995) Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV. Oncogene 10: 2397-2401.
27. Finnberg N, Klein-Szanto AJ, El-Deiry WS, (2008) TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest 118: 111-123.
28. Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, et al. (2007) Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 12: 66-80.
29. Kataoka T, (2005) The caspase-8 modulator c-FLIP. Crit Rev Immunol 25: 31-58.
30. Krueger A, Baumann S, Krammer PH, Kirchhoff S, (2001) FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 21: 8247-8254.
31. Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, et al. (1999) The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med 190: 1025-1032.
32. Medema JP, de Jong J, van Hall T, Melief CJ, Offringa R, (1999) Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 190: 1033-1038.
33. Screpanti V, Wallin RP, Ljunggren HG, Grandien A, (2001) A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. J Immunol 167: 2068-2073.
34. Amanullah A, Liebermann DA, Hoffman B, (2002) Deregulated c-Myc prematurely recruits both Type I and II CD95/Fas apoptotic pathways associated with terminal myeloid differentiation. Oncogene 21: 1600-1610.
35. Ricci MS, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, et al. (2004) Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 24: 8541-8555.
36. Testa U, Riccioni R, (2007) Deregulation of apoptosis in acute myeloid leukemia. Haematologica 92: 81-94.
37. Nyakeriga AM, Djerbi M, Malinowski MM, Grandien A, (2005) Simultaneous expression and detection of multiple retroviral constructs in haematopoietic cells after bone marrow transplantation. Scand J Immunol 61: 545-550.
38. Djerbi M, Darreh-Shori T, Zhivotovsky B, Grandien A, (2001) Characterization of the human FLICE-inhibitory protein locus and comparison of the anti-apoptotic activity of four different flip isoforms. Scand J Immunol 54: 180-189.
39. Djerbi M, Malinowski MM, Yagita H, Zhivotovsky B, Grandien A, (2007) Participation of FLIP, RIP and Bcl-x(L) in Fas-mediated T-cell death. Scand J Immunol 66: 410-421.
40. Karasuyama H, Melchers F, (1988) Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol 18: 97-104.
41. Persons DA, Allay JA, Allay ER, Smeyne RJ, Ashmun RA, et al. (1997) Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo. Blood 90: 1777-1786.
42. Bonham L, MacKenzie K, Wood S, Rowe PB, Symonds G, (1992) Both myeloproliferative disease and leukemia are induced by transplantation of bone marrow cells expressing v-myc. Oncogene 7: 2219-2229.
43. Dolnikov A, Shounan Y, Millington M, Mackenzie K, Symonds G, (1998) V-myc in a simple, single gene retroviral vector causes rapid induction of leukemia and concomitant apoptosis following bone marrow transplantation. Leukemia 12: 542-553.
44. Preisler HD, (1987) The treatment of acute non-lymphocytic leukemia. Blood Rev 1: 97-105.
45. Smith DP, Bath ML, Metcalf D, Harris AW, Cory S, (2006) MYC levels govern hematopoietic tumor type and latency in transgenic mice. Blood 108: 653-661.
46. Felsher DW, Bishop JM, (1999) Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4: 199-207.
47. Green DR, Evan GI, (2002) A matter of life and death. Cancer Cell 1: 19-30.
48. Zornig M, Busch G, Beneke R, Gulbins E, Lang F, et al. (1995) Survival and death of prelymphomatous B-cells from N-myc/bcl-2 double transgenic mice correlates with the regulation of intracellular Ca2+ fluxes. Oncogene 11: 2165-2174.
49. Nieminen AI, Partanen JI, Hau A, Klefstrom J, (2007) c-Myc primed mitochondria determine cellular sensitivity to TRAIL-induced apoptosis. EMBO J 26: 1055-1067.
50. Cameron ER, Morton J, Johnston CJ, Irvine J, Bell M, et al. (2000) Fas-independent apoptosis in T-cell tumours induced by the CD2-myc transgene. Cell Death Differ 7: 80-88.
51. Smith DP, Bath ML, Harris AW, Cory S, (2005) T-cell lymphomas mask slower developing B-lymphoid and myeloid tumours in transgenic mice with broad haemopoietic expression of MYC. Oncogene 24: 3544-3553.